• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
The Genome
CMECNE

MTHFR Polymorphism Testing – The Evidence Isn’t There

image_pdfFavoriteLoadingFavorite

Learning Objectives and CME/Disclosure Information

This activity is intended for healthcare providers delivering care to women and their families.

After completing this activity, the participant should be better able to:

1. Discuss which biologic reactions rely on MTHFR
2. Recall current evidence regarding the clinical utility of screening patients for polymorphic MTHFR variants

Estimated time to complete activity: 0.25 hours

Faculty:

Susan J. Gross, MD, FRCSC, FACOG, FACMG
President and CEO, The ObG Project

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The PIM planners and others have nothing to disclose. The OBG Project planners and others have nothing to disclose.

Faculty: Susan J. Gross, MD, receives consulting fees from Cradle Genomics, and has financial interest in The ObG Project, Inc.

Planners and Managers: The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN, and Jan Schultz, MSN, RN, CHCP have nothing to disclose.

Method of Participation and Request for Credit

Fees for participating and receiving CME credit for this activity are as posted on The ObG Project website. During the period from Dec 31 2017 through Jan 25 2023, participants must read the learning objectives and faculty disclosures and study the educational activity.

If you wish to receive acknowledgment for completing this activity, please complete the post-test and evaluation. Upon registering and successfully completing the post-test with a score of 100% and the activity evaluation, your certificate will be made available immediately.

For Pharmacists: Upon successfully completing the post-test with a score of 100% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and The ObG Project. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.2 contact hours.

Read Disclaimer & Fine Print

WHAT IS IT?

  • 5,10-methylenetetrahydrofolate reductase (MTHFR) enzyme catalyzes 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate and is therefore critical to reactions and processes involving folate
    • MTHFR converts the amino acid homocysteine to methionine
    • MTHFR and consequent folate status impacts pathways involving DNA methylation and gene regulation
  • Two polymorphic variants are known to decrease enzyme activity
    • 677C>T (“thermolabile” variant – enzyme less active at higher temperatures)
      • Commonly, a C is at position 677 that codes for an alanine
      • T at position 677 leads to a valine substitution
    • 1298A>C is also common but does not cause increased homocysteine levels in heterozygous or homozygous individuals
    • Combined heterozygosity of 1298A>C and 677C>T results in an outcome like 677C>T homozygous individuals
  • 677C>T is common and found throughout the world
    • 10 – 15% of North American Caucasians are homozygous
    • > 25% of Hispanics are homozygous with the highest allele frequencies
    • 6% in individuals of African descent are homozygous
    • 20 to 40% of Caucasians or Hispanics in the US are heterozygotes (one allele)
  • Reduced MTHFR activity, especially when folate levels are low, is a risk factor for hyperhomocysteinemia
    • Hyperhomocysteinemia has been weakly associated with venous thrombosis and coronary artery disease
    • Other factors can elevate homocysteine levels (e.g. deficiencies of folate, vitamins B6 and B12)
    • Hyperhomocysteinemia may be mild to moderate in individuals who are homozygotes for MTHFR polymorphisms with limited clinical significance

KEY POINTS:

Is MTHFR genotype status related to disease?

  • Until recently, it was thought that MTHFR deficiency, by causing elevated homocysteine levels, led to an increased risk of venous thrombosis, coronary heart disease, recurrent pregnancy loss and adverse pregnancy outcomes
  • More recent analysis has found no evidence for consistent associations or causation
  • Furthermore, there is no association with MTHFR variants and mortality
  • Homocysteinemia should not be confused with homocystinuria, a rare genetic disease usually seen in childhood, which presents with extremely high homocysteine levels and is associated with severe, early onset vascular disease and venous thromboembolism
  • There is no evidence that it is dangerous to vaccinate children with MTHFR mutations nor is testing of children for this reason indicated

Is there clinical utility to clinical testing for MTHFR variants?

  • MTHFR is only one factor in hyperhomocysteinemia
  • Fortification of cereals has led to higher folate levels and therefore reduced homocysteine levels
    • Due to gene-nutrient interaction, previous associations between MTHFR variants and disease may no longer be relevant
    • For example, the association between 677C>T and venous thromboembolism is no longer seen in the US
  • Lowering homocysteine levels through vitamin supplementation does not reduce the risk of blood clots or cardiovascular disease

RECOMMENDATIONS:

MTHFR polymorphism genotyping should not be ordered as part of the clinical evaluation for thrombophilia, recurrent pregnancy loss, or for at-risk family members.

  • ACOG
    • Testing for MTHFR mutations in not recommended for recurrent pregnancy loss, as only antiphospholipid syndrome has shown consistent associations
    • MTHFR variants in isolation do not confer additional risk for thrombosis in either pregnant or nonpregnant women and therefore testing for MTHFR variants or fasting homocysteine levels in not recommended for the work up of venous thromboembolism
    • There is lack of association between heterozygosity or homozygosity for 677C>T and any negative pregnancy outcomes
  • ASRM and NSGC
    • Testing for MTHFR variants for recurrent pregnancy loss is not recommended
  • ACMG
    • MTHFR polymorphism genotyping should not be ordered as part of the clinical evaluation for thrombophilia or recurrent pregnancy loss or for at-risk family members
    • Do not adjust preventative folic acid supplementation dose for NTDs based on MTHFR results
  • Thrombosis Canada
    • Due to lack of clinical utility and available data, treating hyperhomocysteinemia in patients with cardiovascular disease or VTE is not recommended, nor is vitamin supplementation for primary prevention of cardiovascular disease recommended
  • Joint Statement on Expanded Carrier Screening (ACOG/ACMG/NSGC/PQF/SMFM)
    • It may be preferable not to include variants on expanded prenatal genetic carrier panels that have high allele frequencies and low penetrance of a phenotype such as MTHFR

Learn More – Primary Sources:

Prevalence of methylenetetrahydrofolate reductase 677T and 1298C alleles and folate status: a comparative study in Mexican, West African, and European populations 

MTHFR related hyperhomocysteinemia

ACOG Committee Opinion 197: Inherited Thrombophilias in Pregnancy

ASRM: Evaluation and treatment of recurrent pregnancy loss: a committee opinion 

ACMG Practice Guideline: lack of evidence for MTHFR polymorphism testing

MTHFR: Addressing Genetic Counseling Dilemmas Using Evidence-Based Literature 

Meta-analysis of MTHFR 677C->T polymorphism and coronary heart disease: does totality of evidence support causal role for homocysteine and preventive potential of folate?

Expanded carrier screening in reproductive medicine-points to consider: a joint statement of the American College of Medical Genetics and Genomics, American College of Obstetricians and Gynecologists, National Society of Genetic Counselors, Perinatal Quality Foundation, and Society for Maternal-Fetal Medicine

AAP: Immunizations and Common Parental Concerns

Take a post-test and get CME credits

TAKE THE POST TEST

Want to hear about the latest clinical summaries?

Get Your Free Newsletter »

image_pdfFavoriteLoadingFavorite

< Previous
All The Genome Posts
Next >

Related ObG Topics:

When to Stop Anticoagulation Following a DVT or Pulmonary Embolus?
ACOG Opinion on Expanded Carrier Screening
Practical info on evidence based medicine for your women's healthcare practice
Recurrent Miscarriage – does progesterone improve outcomes?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site